Published in Ann Gen Psychiatry on June 13, 2014
An HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine. Sci Rep (2015) 0.80
Ethiopathogenesis of depressive disorders. Clin Pract Epidemiol Ment Health (2014) 0.75
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 45.33
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (1996) 16.04
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA (2010) 13.88
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
A meta-analysis of cytokines in major depression. Biol Psychiatry (2009) 7.16
Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet (2012) 5.99
Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci (2006) 5.70
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
The Bayesian revolution in genetics. Nat Rev Genet (2004) 4.50
Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry (2006) 3.73
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci (2004) 2.76
Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry (2012) 2.67
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav (1997) 2.67
The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol (2010) 2.64
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry (2010) 2.41
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry (2008) 2.35
Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology (2010) 2.29
A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry (2009) 2.15
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry (2011) 2.06
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med (2011) 1.45
STAR*D: revising conventional wisdom. CNS Drugs (2009) 1.41
Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J (2009) 1.35
Association of the 5- HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med (2010) 1.34
Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry (2013) 1.34
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol (2011) 1.33
Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci (2009) 1.30
Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology (2011) 1.27
Intermediate phenotypes in psychiatric disorders. Curr Opin Genet Dev (2011) 1.27
Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res (1999) 1.25
The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions. Biol Psychiatry (2011) 1.21
Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun (2012) 1.18
Genome-wide DNA methylation scan in major depressive disorder. PLoS One (2012) 1.17
CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf) (2012) 1.15
Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med (2014) 1.14
Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists. Trends Pharmacol Sci (2011) 1.13
HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology (2008) 1.12
BDNF Val66Met is associated with introversion and interacts with 5-HTTLPR to influence neuroticism. Neuropsychopharmacology (2009) 1.11
Gene environment interaction studies in depression and suicidal behavior: An update. Neurosci Biobehav Rev (2013) 1.07
The truth about genetic variation in the serotonin transporter gene and response to stress and medication. Br J Psychiatry (2011) 1.07
Gene-environment interactions in common mental disorders: an update and strategy for a genome-wide search. Soc Psychiatry Psychiatr Epidemiol (2013) 1.07
Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2013) 1.03
Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther (2008) 1.00
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One (2013) 0.97
Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J (2010) 0.94
Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res Bull (2011) 0.94
Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.92
Brain galanin system genes interact with life stresses in depression-related phenotypes. Proc Natl Acad Sci U S A (2014) 0.91
A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res (2013) 0.90
Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) (2009) 0.90
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics (2013) 0.90
Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol (2012) 0.89
Endophenotype, intermediate phenotype, biomarker: definitions, concept comparisons, clarifications. Depress Anxiety (2013) 0.87
Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression. Pharmacogenet Genomics (2012) 0.86
Strong effects of environmental factors on prevalence and course of major depressive disorder are not moderated by 5-HTTLPR polymorphisms in a large Dutch sample. J Affect Disord (2012) 0.85
A new clinical evidence-based gene-environment interaction model of depression. Neuropsychopharmacol Hung (2012) 0.85
Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol (2008) 0.84
The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub (2013) 0.83
Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol (2011) 0.83
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl) (2013) 0.82
Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med (2012) 0.80
Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol (2012) 0.80
Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. J Affect Disord (2010) 0.79
Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord (2011) 0.79
Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. J Clin Psychopharmacol (2011) 0.79
Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man. Pharmacol Biochem Behav (2013) 0.79
Biomarkers for personalised treatment in psychiatric diseases. Expert Opin Med Diagn (2013) 0.77
Kynurenines in cognitive functions: their possible role in depression. Neuropsychopharmacol Hung (2012) 0.76